IL-22 is required for Th17 cell–mediated pathology in a mouse model of psoriasis-like skin inflammation
J. Clin. Invest. Hak-Ling Ma, et al. 118:597 doi:10.1172/JCI33263 [Go to this article.]

Figure 4
IL-22 neutralization prevents the development of skin lesions. (A) Left panel shows the mean disease severity (±SEM) in recipient mice that were given 16 mg/kg of IL-22 (IL22-104) or isotype control antibody, i.p. once per week for 11 weeks. *P < 0.05 starting on day 26, comparing the 2 groups, with n = 10 mice. Right panel shows the disease severity scores at the end of the study. Data are representative of at least 2 independent experiments. (B and C) H&E-stained sections of ear tissue from recipients given an isotype control (left) or IL-22 antibody (right). Original magnification, ×200 (B) and ×400 (C). (D) Epidermal thickness and semiquantitative scoring of basilar papillae and inflammatory infiltrates in the indicated skin layers. A section from each mouse ear was scored as follows: 0, within normal limits; 1, minimal; 2, mild; 3, moderate; 4, marked; and 5, severe. Means ± SEM are shown, with n = 10 mice. (E and F) Representative immunohistochemical staining for CD11b⁺ (E) and CD4⁺ (F) in ear sections from recipients given isotype control antibody (left) or IL-22 antibody (right). Original magnification, ×400. (G) Mean disease severity in recipient mice after cell transfer and subsequent weekly treatment starting on day 14 with 16 mg/kg of IL-22 (IL22-103) or isotype control antibody (as indicated by arrow). *P < 0.05 on day 46 comparing the 2 groups (n = 10 mice). Right panel shows individual disease severity scores at the end of the study.